BRCA1 / BRCA2

BRCA1 and BRCA2 are tumor-suppressor genes that help repair DNA double-strand breaks through homologous recombination. A pathogenic germline variant can cause hereditary breast and ovarian cancer predisposition and can affect relatives. A pathogenic somatic variant is confined to the tumor unless germline testing shows otherwise. [B1-B5]

BRCA results have two separate clinical uses: inherited-risk assessment and treatment selection. Tumor-only testing can suggest a possible inherited variant but cannot reliably determine germline status; confirmatory germline testing and genetic counseling may be needed. [B1-B3]

BRCA1 coordinates DNA-damage sensing, end resection, checkpoint control, chromatin regulation, and recruitment of repair machinery. BRCA2 directly supports loading of RAD51 onto single-stranded DNA so homologous recombination can copy information from an intact template. Loss of both functional alleles can create homologous-recombination deficiency, genomic instability, and dependence on alternative repair pathways. [B4-B5]

BRCA1 and BRCA2 are not interchangeable. They have overlapping homologous-recombination functions but different protein partners, tumor spectra, and phenotype associations. A pathogenic variant in one allele is inherited in an autosomal-dominant predisposition pattern, while tumor formation usually involves loss or inactivation of the remaining functional allele. [B1-B2]

Pathogenic germline BRCA1/2 variants are strongly associated with female breast, ovarian, fallopian-tube, and primary peritoneal cancers. BRCA2 is particularly relevant to male breast cancer; both genes are associated with pancreatic and prostate cancer, with gene-specific differences. [B1-B2]

BRCA-associated biology can also be present through somatic changes in tumors. Not every cancer in a carrier is necessarily caused by BRCA loss, and not every tumor BRCA variant creates homologous-recombination deficiency. [B2]

Germline testing can establish a molecular diagnosis of hereditary cancer predisposition when a pathogenic or likely pathogenic variant is found in the correct clinical context. This can influence screening, prevention, surgical discussion, and cascade testing of biological relatives. [B1-B3, B6]

Tumor testing identifies somatic and possible germline alterations for therapy selection. If tumor-only testing finds a BRCA pathogenic variant, the report should state that germline origin cannot be determined from the tumor result alone and recommend genetics evaluation where appropriate. [B1-B3]

BRCA status is not a universal prognosis calculator. In ovarian cancer, BRCA-associated homologous-recombination deficiency is often linked to platinum sensitivity, but prognosis depends on stage, surgery, treatment, reversion-mediated resistance, and other factors. In breast, pancreatic, and prostate cancer, outcomes differ by disease subtype and treatment exposure. [B2, B8]

A pathogenic germline variant predicts future cancer risk at the person and family level, but penetrance is incomplete and modified by age, sex, family history, reproductive factors, other genes, and environment. Individual risk estimates should come from genetics professionals using current models rather than a website summary. [B1-B2]

BRCA1/2 pathogenic variants can predict benefit from PARP inhibitors in selected ovarian, breast, pancreatic, and prostate-cancer settings. Exact eligibility may require germline, somatic, or broader homologous-recombination-repair criteria depending on the drug and disease. [B8-B10]

BRCA-deficient tumors can be sensitive to platinum agents because these drugs create DNA lesions that require homologous recombination for repair. Sensitivity is not guaranteed, and prior platinum response, reversion mutations, and disease setting matter. [B8, B11-B14]

An HRD genomic-scar score is not equivalent to a BRCA pathogenic variant. Conversely, a BRCA variant does not always prove biallelic loss or current HR deficiency. [B2, B8]

A germline BRCA result is stable across life and is not serially monitored. Clinical surveillance focuses on cancer risk and organ-specific screening, not change in the inherited variant. [B1-B3]

In treated cancer, ctDNA research can track BRCA reversion mutations or other resistance alterations. These approaches may be clinically available in selected advanced cancers, but routine MRD or resistance monitoring is not standardized across all BRCA-associated cancers. [B15-B16]

Germline multigene panel: NGS of coding regions and splice boundaries, usually combined with deletion/duplication analysis to detect exon-level or whole-gene rearrangements. Blood and saliva are common specimens. [B1-B3]

Targeted familial-variant testing: tests only a known family variant and is appropriate after a familial pathogenic variant has been established.

Tumor NGS: detects somatic variants, copy-number changes, and sometimes loss of heterozygosity. Tumor assays have different validation and may not reliably detect all germline alteration types. [B2-B3]

Paired tumor-normal sequencing: compares tumor with normal DNA and more clearly separates somatic from germline findings.

RNA studies or functional assays: may help resolve selected splice or uncertain variants, generally through specialized laboratories. [B6]

Constitutional variants are commonly classified using a five-tier framework: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign. Reports should include gene, transcript, HGVS notation, zygosity, classification, evidence summary, testing limitations, and whether deletion/duplication analysis was performed. [B6]

Tumor reports should specify somatic/germline uncertainty, variant allele fraction, tumor purity, copy-number or loss-of-heterozygosity findings, and whether the result meets a current therapy label. A VUS must not be relabeled as "positive." [B1-B3, B6]

A negative test can mean no reportable variant was found in the genes and regions tested; it does not remove all hereditary risk, especially when no affected relative has been tested or the family history suggests another gene. [B1-B3]

A pathogenic germline BRCA1/2 variant can explain inherited susceptibility and has implications beyond the patient. Pre-test and post-test genetic counseling help address informed consent, relatives, reproductive choices, privacy, and psychosocial effects. [B1-B3]

A pathogenic tumor BRCA alteration may support PARP-inhibitor eligibility in a defined cancer setting, but interpretation requires disease, treatment line, germline status, biallelic function, prior platinum exposure, and current regulatory labeling. [B8-B10]

A VUS is an unresolved scientific finding. Medical management should generally be based on personal and family history rather than the VUS itself, and laboratories may later reclassify it. [B6]

Direct-to-consumer tests may cover only a small subset of BRCA variants and can miss most clinically relevant changes. Positive and negative consumer results may require confirmation in a clinical laboratory. [B1-B3]

Tumor-only testing can be confounded by low purity, copy-number complexity, formalin damage, and inability to determine inherited origin. Blood-based tumor testing can also be affected by clonal hematopoiesis, although BRCA findings require case-specific evaluation. [B3]

Variant classification can differ between laboratories and change as evidence grows. Ancestry underrepresentation in reference databases can increase VUS rates. Large rearrangements, deep intronic changes, mosaicism, or structural variants may be missed if the assay is not designed for them. [B2, B6]

BRCA reversion mutations can restore the reading frame and functional homologous recombination, producing resistance to platinum or PARP inhibitors. Multiple independent reversions can emerge in the same patient. [B15-B16]

Other mechanisms include restoration of DNA-end resection through loss of 53BP1-pathway factors, stabilization of stalled replication forks, altered PARP1, reduced drug trapping, drug-efflux changes, and activation of alternative survival pathways. These are not captured by a baseline BRCA result alone. [B15-B16]

Resistance is clinically heterogeneous. A tumor may remain BRCA-mutated on a standard report while functionally regaining DNA repair through a secondary event. Repeat tissue or ctDNA testing can sometimes reveal this, but standardized treatment algorithms are still developing. [B15-B16]

PARP inhibitors: olaparib, rucaparib, niraparib, and talazoparib are approved in different BRCA- or HRR-defined settings. Each label specifies cancer type, line of therapy, germline versus somatic criteria, and companion diagnostic. [B8-B10]

Platinum chemotherapy: cisplatin, carboplatin, and oxaliplatin create DNA damage that can exploit homologous-recombination deficiency, but are not BRCA-specific drugs.

Combination approaches: PARP inhibitors are combined with androgen-receptor-pathway therapy in selected prostate cancers and are under study with immunotherapy, antiangiogenic therapy, ATR/WEE1 inhibitors, or other DNA-damage-response agents. [B9]

Risk-reduction surgery and organ-specific screening are prevention strategies for germline carriers, not drug classes; they require separate guideline-based counseling. [B1-B2]

Earlier prostate-cancer use: in December 2025, the U.S. FDA approved niraparib plus abiraterone and prednisone for deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer identified by an approved test. [B9]

Confirmatory evidence and refined labels: in December 2025, the U.S. FDA granted regular approval to rucaparib for previously androgen-receptor-directed, deleterious germline and/or somatic BRCA-mutated metastatic castration-resistant prostate cancer. [B10]

Research priorities: functional HRD measurement rather than genotype alone, identification of biallelic loss, ctDNA detection of reversion mutations, rational post-PARP combinations, and improved variant interpretation across ancestries. [B2, B15-B16]

Clinical caution: regulatory history for PARP inhibitors has changed in several diseases as confirmatory survival data matured. The website should link to the current local label rather than maintain a static list of all historical indications. [B8-B10]

Regulatory statements describe U.S. FDA indications and should be checked against the current label for the user's country or region.